We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OPY:NYSEOppenheimer Holdings, Inc. Analysis

Data as of 2026-06-03 - not real-time

$95.09

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Oppenheimer Holdings is trading near its 20‑day simple moving average while remaining below the 50‑day average, indicating a neutral technical stance. The RSI hovers just under the midpoint, and the MACD has turned bullish, offering a modest upside bias. However, the stock exhibits high 30‑day volatility and a beta slightly above one, suggesting price swings may be pronounced. Fundamentally, the trailing P/E is well under the sector average, the price‑to‑book hovers around parity, and the dividend yield is modest but supported by a very low payout ratio. A discounted cash‑flow model values the company at roughly double its current market price, pointing to significant undervaluation despite a recent quarterly loss that followed strong revenue growth of over twenty percent. The balance sheet shows near‑net cash but an elevated debt‑to‑equity ratio, which tempers the upside narrative. Overall, the blend of attractive valuation metrics, sustainable dividend, and growth‑oriented earnings creates a compelling case for investors willing to navigate short‑term volatility.
Investors should weigh the earnings miss and debt profile against the long‑term upside implied by the DCF, while the dividend offers a modest income cushion.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Quarterly earnings miss despite revenue growth
  • Neutral technical positioning with bullish MACD hint
  • Modest dividend provides limited downside cushion

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF valuation indicates substantial upside
  • Revenue growth outpacing the sector
  • Low payout ratio supports dividend sustainability

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervaluation relative to fundamentals and peers
  • Strong cash position offsetting debt concerns
  • Consistent dividend with low payout ratio enhances total return

Key Metrics & Analysis

Financial Health

Revenue Growth23.10%
Profit Margin5.96%
P/E Ratio11.3
ROE10.53%
ROA2.62%
Debt/Equity145.37
P/B Ratio1.1
Op. Cash Flow$90.5M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI47.1
Support$90.00
Resistance$100.00
MA 20$94.65
MA 50$99.10
MA 200$81.37
MACDBullish
VolumeIncreasing
Fear & Greed Index92.73

Valuation

Fair Value$204.22
GradeUndervalued
TypeBlend
Dividend Yield0.84%

Risk Assessment

Beta1.04
Volatility50.64%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.